Alkermes announced the initiation of ARTISTRY-7, a global Phase 3, open-label, randomized trial evaluating the anti-tumor activity and safety of intravenously administered nemvaleukin alfa, in combination with Keytruda, compared to investigator's choice chemotherapy, in patients with platinum-resistant ovarian cancer. Nemvaleukin, Alkermes' lead immuno-oncology candidate, is a novel, investigational, engineered IL-2 variant immunotherapy. As previously announced, ARTISTRY-7 is being conducted in collaboration with Merck & Co, which is providing Keytruda for the study. In addition, Alkermes is working with The GOG Foundation and ENGOT to conduct the study. FDA recently granted Fast Track designation to nemvaleukin in combination with pembrolizumab for the treatment of platinum-resistant ovarian cancer.